Semaglutide for Inflammation: What the Evidence Shows
What human and animal studies show about Semaglutide for inflammation, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 5
- PubMed records, our ledger
- Animal studies
- 0
- PubMed records, our ledger
- Studies we summarised
- 2
- with an outcome for inflammation
Evidence for inflammation
Each row is an outcome related to inflammation from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Carotid plaque inflammation | No significant difference between semaglutide and placebo in carotid plaque inflammation at week 26. | Human RCTn = 101 | American heart journal 2025, PMID 40345413 |
| C-reactive protein | C-reactive protein changed by -43.5% with semaglutide vs -7.3% with placebo. | Human RCTn = 529 | The New England journal of medicine 2023, PMID 37622681 |
PubMed records for Semaglutide and inflammation: 5 human, 0 animal (search counts, not studies we reviewed). Grades follow our evidence scale.
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for inflammation
All peptides for inflammation, comparedCommon questions
Does Semaglutide help with inflammation?
The strongest study we summarise for inflammation is human rct evidence, across 2 studies with an outcome for inflammation. A trial result is not an approval; see the legal status.
Is Semaglutide approved for inflammation?
Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for inflammation?
There is no single answer. Our inflammation overview compares each candidate by evidence grade and legal status rather than by popularity.
More on Semaglutide
Sources
- 1Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.American heart journal · 2025PMID 40345413Accessed 2 Oct 2026
- 2Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2023PMID 37622681Accessed 2 Oct 2026
Found an error? Report a correction.